Oncogene-mediated premature senescence has emerged as a potential tumor-suppressive mechanism in early cancer transitions. Many studies showed that Ras and p38 mitogen-activated protein kinase (MAPK) participate in premature senescence. Our previous work indicated that the HMG box-containing protein 1 (HBP1) transcription factor is involved in Ras-and p38 MAPK-induced premature senescence, but the mechanism of which has not yet been identified. Here, we showed that the p16 INK4A cyclin-dependent kinase inhibitor is a novel target of HBP1 participating in Ras-induced premature senescence. The promoter of the p16
Introduction
Cellular senescence appears to be functioning as a barrier to cancer, preventing damaged cells from undergoing aberrant proliferation (Bodnar et al., 1998; Bond et al., 1999; Bulavin et al., 2002) . In general, there are two types of senescence: replicative senescence and premature senescence. Normal cells undergo a limited number of population doublings (PD) before entering replicative senescence, which is a consequence of telomere shortening due to repeated cell divisions. Premature senescence can be triggered by many stimuli, including oncogene imbalance. Like replicative senescence, oncogene-induced premature senescence is identified by senescence biomarkers such as senescenceassociated b-galactosidase (SA-b-gal) (Dimri et al., 1995) , and is accompanied by increased expression of negative growth regulators including p53, p21 WAF1 and p16
INK4A (Bandyopadhyay et al., 2001; Bennett, 2003; Ohtani et al., 2004; Takahashi et al., 2006; Haferkamp et al., 2008) . Several recent studies have shown that oncogene-induced premature senescence indeed occurs in premalignant human tumors and provides an initial barrier to tumor genesis in vivo (Hornsby, 2007; Acosta et al., 2008; Ansieau et al., 2008) .
One well-characterized type of oncogene-induced premature senescence is that induced by oncogenic Ras (Hunter, 1991; Molnar et al., 1997; Hahn et al., 1999; Elenbaas et al., 2001) . In contrast to its mitogenic activity, expression of oncogenic Ras in normal primary cells induces premature senescence (Serrano et al., 1997; Lin et al., 1998) . Interestingly, the ability of oncogenic Ras to induce premature senescence depends on the Raf/ MEK/ERK pathway that mediates cell proliferation. Further investigation revealed that the Raf/MEK/ERK pathway and MKK3/6-p38 pathway are sequentially activated to mediate oncogenic Ras-induced premature senescence (Wang et al., 2002) . Actually, Raf/MEK/ ERK and MKK3/6-p38 represent two independent mitogen-activated protein kinase (MAPK) pathways. Whereas the Raf/MEK/ERK cascade transduces proliferative signals, the MKK3/6-p38 cascade is a major mediator of stress responses that usually leads to growth arrest or apoptosis (Kim et al., 2002; Xiu et al., 2003; Bulavin and Fornace, 2004; Yee et al., 2004) . It was reported that the MKK3/6-p38 cascade functions as downstream of the Raf/MEK/ERK cascade to mediate senescence. Taken together, p38 MAPK has important causative functions in senescent cells following Ras induction or oxidative stress.
HMG box-containing protein 1 (HBP1) is homologous to the sequence-specific high mobility group (HMG) family of transcriptional factors (Yee et al., 1999; Zhuma et al., 1999; Berasi et al., 2004) . We have previously isolated HBP1 as a retinoblastoma partner and have determined that it functions as a proliferation regulator by inhibiting oncogenic pathways as a transcriptional repressor (Lavender et al., 1997; Tevosian et al., 1997; Shih et al., 1998 Shih et al., , 2001 Lemercier et al., 2000; Smith et al., 2004) . Recently, the HBP1 transcriptional repressor has been reported as a putative substrate for the p38 MAPK in cell-cycle arrest (Xiu et al., 2003) . Mechanistically, p38 MAPK-mediated phosphorylation of the HBP1 leads to increased protein stability and a G 1 arrest. Moreover, our previous work showed that HBP1 participates in Ras-and p38 MAPKinduced premature senescence . In that work, we investigated the role of HBP1 in a premature senescence pathway. We found that HBP1 is necessary for premature senescence by Ras-p38 MAPK. Furthermore, HBP1 itself also induces premature senescence that is associated with an increase of the p16
INK4A . Together, the data from our previous study support a model in which HBP1 is a downstream effector of Ras, and p38 MAPK, and provide new insights into the signaling mechanisms that lead to premature senescence.
HBP1 is a transcriptional factor. How does HBP1 regulate senescence? The downstream target of HBP1 in premature senescence has not been identified. In our previous work, we mentioned that p16
INK4A always increases significantly in Ras, p38 MAPK or HBP1-induced premature senescence. In this study, we investigated whether p16
INK4A is a relevant downstream target in the Ras/p38 MAPK/HBP1-mediated senescence pathway. Furthermore, we found that HBP1 knockdown cells are easily transformed by Ras, whereas p16
INK4A knockdown with shRNA only delays Rasinduced premature senescence. Thus, decreases in the HBP1 gene can substitute for three of the four activities known to elicit in vitro transformation and also trigger full-blown tumors in mice. Our study results revealed a novel activity of the HBP1/p16
INK4A pathway and increased our understanding of how cellular senescence and transformation are controlled in human primary cells. The results of our study further highlight the importance of HBP1 in tumor-suppressive functions. et al., 2007) . Relevant mutants from our previous work are shown in Figure 3b . The proteins could be expressed stably in 293T cells (Figure 3c ). To test whether HBP1 expression activated transcription of the p16 INK4A promoter, we co-transfected 293T cells with HA-tagged HBP1 or mutants and the p16 INK4A promoters with distinct length. Wild-type HBP1 expression activated the p16 INK4A promoter that contains the HBP1 affinity site (Figure 3d , 599, 620, 870 and 2070), whereas HBP1 had no effect on the p16 INK4A promoters of 280 and 399, both of which lack the affinity site. To dissect the requirement for DNA binding, we used two mutants, pmHMG and delEx7. pmHMG carries a triple-point mutation in the HMG box DNA-binding domain that abolishes DNA binding. The delEx7 mutant was isolated in our breast cancer study and represents a naturally occurring mutant of HBP1 that is associated with invasive breast cancer (Paulson et al., 2007) . The exon-skipping deletion in delEx7 creates a premature termination signal, resulting in the deletion of the DNA-binding domain and much of the repression domain. Neither pmHMG nor delEx7 enhanced p16
INK4A promoter (Figure 3d ). promoter.
Another two mutants of HBP1, D218-314 (part deletion in repression domain in position 218-314 residues) and D199-400 (whole deletion in repression domain in position 199-400 residues) were used to test whether the repression domain was required for p16 INK4A promoter transactivation. As shown in Figure 3e , both D218-314 and D199-400 had the same effect on p16 INK4A promoters (length of 399 and 599, respectively) compared with wild-type HBP1. This means that the repression domain of HBP1 does not mitigate the enhancement of p16 INK4A promoter activation. We next tested the effect of HBP1 protein availability on p16 INK4A promoter activation. With the addition of exogenous HBP1, the relative activity of the native p16
INK4A
promoter increased significantly in a dose-dependent manner ( Figure 3f ).
HBP1 occupies its affinity site in the p16
INK4A promoter Because overexpression of HBP1 resulted in enhanced p16 INK4A promoter activity, we then decided to test whether HBP1 could bind the p16 INK4A gene promoter and increase its protein expression. The electrophoretic mobility shift assay (EMSA) assay provides a complementary demonstration that HBP1 binds specifically to its affinity site. With 293T nuclear extracts, the EMSA experiments shown in Figures 4a-c showed that the endogenous HBP1 could bind to the specific oligonucleotide probe (containing affinity site and 32 P-labeled: gggttgagggggtagggggac, probe N), and the transfected wild-type HBP1, but not mutant HBP1 with point mutation in the HMG DNA-binding domain (pmHMG), or deletion of the DNA-binding domain (delEx7), resulted in increased HBP1 binding. Furthermore, the HBP1 band is specific, as determined by competition with 100-fold excess of unlabeled probe N. In addition, the stronger band in the transfected HA-HBP1 lanes can be further shifted when anti-HA is included in the binding reaction, which confirmed that HBP1 specially binds probe N ( Figure 4a ).
To further determine the specificity of HBP1 affinity site, we designed two mutant oligonucleotides, each of them has one-point mutation in the affinity site, the oligonucleotides are named probe A and probe T (gggttgagggggAagggggac, probe A; gggttgagggggt Tgggggac, probe T). Probe A and probe T were used as cold probes to compete with probe N ( showed that HMG box is indispensable for DNA binding.
Our studies showed that the level of HBP1 protein increases with advancing PD during replicative senescence (Figure 1d ). Therefore, we asked whether HBP1 could preferentially bind the p16 INK4A promoter in senescent cells. As shown in Figure 4d , with WI-38 nuclear extracts, the EMSA experiments showed that endogenous HBP1 in senescent cells could bind p16
INK4A
promoter more strongly than in young cells. The data confirmed our hypothesis that HBP1 has the potential of enhancing p16
INK4A promoter in senescent cells. Thus HBP1 upregulates p16
INK4A expression in senescent cells.
The binding of HBP1 to the endogenous p16 promoter was determined by a chromatin immunoprecipitation (ChIP) assay (Figure 4e ). The interaction with a p16 INK4A promoter region that contains the HBP1 affinity site was detected by a specific PCR assay of immunoprecipitated HBP1/DNA complexes. Immunoprecipitation with anti-GAPDH was used as a negative control. Here, HA-tagged HBP1 or mutants were used to test interaction between HBP1 (or mutant) protein and the regulatory region of the endogenous p16
promoter. As shown in Figure 4e , HBP1 is bound to the endogenous p16
INK4A promoter in the region of affinity site. As a control, pmHMG or delEx7, which is defective (a) EMSA assays were performed by using a radiolabeled doublestranded probe consisting of one HBP1 affinity site (gggttgagggggtagggggac, probe N). Nuclear extracts (10 mg) from HEK-293T cells transfected with or without HBP1 expression plasmid were used. Cold competitors were included in the indicated lanes at 100-fold excess. The presence of specific complexes, including supershifted HA/HBP1 in the complexes, is indicated by arrows. (b) EMSA assays were performed by using a radiolabeled probe N. Nuclear extracts (10 mg) from HEK-293T cells transfected with or without HBP1 mutant delEx7 expression plasmid were used. The mutant probe A (gggttgagggggAagggggac) or probe T (gggttgagggggtTgggggac) was used as cold competitor. Cold competitors were included in the indicated lanes at 100-fold excess. The experiment was performed as panel (a). (c) EMSA assays were performed by using a radiolabeled probe N. Nuclear extracts (10 mg) from HEK-293T cells transfected with or without HBP1 mutant pmHMG expression plasmid were used. The mutant probe A (gggttgagggggAaggg ggac) or probe T (gggttgagggggtTggg ggac) was used as cold competitor. Cold competitors were included in the indicated lanes at 100-fold excess. The experiment was performed as panel (a). (d) EMSA assays were performed by using a radiolabeled probe N. Nuclear extracts (10 mg) from young (PD15) or senescent (PD50) WI-38 cells were used. Cold competitors were included in the indicated lanes at 100-fold excess. (e) ChIPs were used to test the binding of exogenous HBP1 to the endogenous p16 INK4A gene. HEK-293T cells were transfected with HBP1 or the indicated mutant plasmids. The region from position À272 to À699 contains the HBP1 element and was analyzed by specific PCR. Anti-HA antiserum was used in the indicated lanes. Only lanes with HBP1 proteins that contain intact HMG box show the capability of binding to the p16 INK4A promoter. At the bottom, anti-HA western immunoblotting (IB) for HBP1 protein expression is shown. (f) ChIPs were used to test the binding of endogenous HBP1 to the endogenous p16 INK4A gene. Young (PD10) and senescent (PD50) WI-38 cells were used. Anti-HBP1 antibody was used in the indicated lanes. The experiment was performed as described in (e). (g) ChIPs were used to test whether Ras increases HBP1 binding to the p16 INK4A promoter. Cells transfected with or without Ras were used. Anti-HBP1 antibody was used in the indicated lanes. The experiment was performed as described in (e). promoter. Similarly, D218-314 HBP1, which contains HMG box though lacks a part of the repression domain, also bound the endogenous p16 INK4A promoter. It was obvious that in each control condition, no specific DNA was detected. Western blot analysis showed that protein expression level was similar in each transfection condition (wild type and mutant; Figure 4e , bottom). These results showed that HBP1 could bind specifically to the endogenous p16 INK4A promoter. In addition, we used HBP1 antibody in ChIP assay to further confirm the conclusion and test whether the binding increases in senescent cells. As shown in Figure 4f , the endogenous HBP1 was definitely bound to the p16 INK4A promoter in both of young and senescent cells. The binding increased in senescent cells, consistent with the previous result that HBP1 expression increases with the advancing population doubles (Figure 1d) .
Next, we intended to test whether Ras would increase HBP1 binding to the p16
INK4A promoter. As shown in Figure 4g , the binding increases in Ras induction cells, consistent with the previous result that HBP1 and p16
INK4A expression increase in Ras induction cells. (Figure 5a ), designated as pmA (point mutation at position À430: change T to A) and pmT (point mutation at position À429: change A to T). 293T cells were then cotransfected with HBP1 and luciferase reporters with native p16 INK4A promoter (length of 599 bp from transcriptional origin, pN) or mutant p16
INK4A promoters of pmA and pmT. HBP1 failed to activate both luciferase reporters with p16
INK4A promoter mutations (pmA and pmT, Figure 5b ), whereas it increased native p16 INK4A promoter (pN) activity significantly as previously reported. The result indicated that HBP1 would lose the capability of enhancing p16
INK4A promoter in vivo if it contained one point mutant in the affinity site. The integrity of affinity site is indispensable for HBP1 enhancing p16
INK4A promoter in vivo.
p16
INK4A promoter activity is enhanced by Ras and MKK6E It has previously been shown that p38 MAPK activation is necessary for Ras-induced senescence and that p38 MAPK activation is sufficient to induce senescence (Haq et al., 2002; Iwasa et al., 2003; Deng et al., 2004; Nelyudova et al., 2007; Kim et al., 2008) . Our previous data revealed that HBP1 is a downstream effector of Ras, and p38 MAPK . Therefore, we asked whether p16
INK4A was required for p38 MAPKinduced senescence. MKK3 and MKK6 represent redundant kinases that can activate p38 MAPK signaling (Raingeaud et al., 1996) . MKK6E is dominant positive for p38 MAPK activation due to glutamate substitutions at Ser207 and Thr211. Then we tested the relative activity of Ras and MKK6E on the native p16 INK4A promoter with luciferase assay. As shown in Figure 6 , either Ras (Figure 6a INK4A promoters (pmA and pmT). Transfections were performed as described previously. 
HBP1 knockdown facilitates Ras-induced transformation
We reported previously that HBP1 knockdown delays Ras-induced premature senescence in WI-38 cells in early passage . But what could be the result if HBP1 knockdown or p16 INK4A knockdown with shRNA in Ras-induced transformation in vivo? As shown in Figure 7 , p16INK4A knockdown (shRNA) could only delay Ras-induced premature senescence in WI-38 cells in late passage (PD40), but did not show signs of transformation. However, when WI-38 fibroblasts were co-transfected with HBP1shRNA and with RAS and then selected for 14 days in late passage (PD40), the cells were efficiently transformed, as shown by an altered morphology and anchorage-independent growth in soft agar (Figures 7a-c) . Furthermore, these transformed cells expressing an HBP1shRNA and RAS formed xenograft tumors in NOD-SCID mice, thus underscoring tumorigenicity (Figure 7e) . The resulting subcutaneous xenograft tumors from HBP1 KD and RAS expression had an unusually aggressive morphology and appeared to invade into the local musculature (Figure 7f) . Consistent with transformation, the HBP1KD-RAS WI-38 cells expressed mRNA for hTERT and c-myc in WI-38 transfected cells in late passage on HBP1 KD (Figure 7d ). Most standard transformation protocols require exogenous TERT and MYC expression (Zhao et al., 2003) , whereas the reduction of the HBP1 gene appeared to increase both TERT and MYC, in addition to reducing p16 does not facilitate transformation. Yet, the knockdown of the HBP1 gene does facilitate full tumorigenesis, as shown by the tumorigenic growth in mice. Furthermore, these tumors had an invasive character, suggesting a particularly aggressive type. Abrogation of senescence mediated by p16
INK4A is certainly part of the mechanism of tumorigenic transformation, but there remain other mechanisms triggered by HBP1 reductions that also contribute to this complex process of tumorigenesis. As shown in this study, the reduction in p16
INK4A with decreases in HBP1 does contribute to the regulation of senescence, but other HBP1 gene targets must collaborate to give this aggressive tumor type. The in vitro transformation of primary cells has been extensively studied and usually requires a combination of exogenous TERT, SV40 early region, MYC and RAS (Zhao et al., 2003) . Essentially, decreases in HBP1 replace three of the four activities associated with transformation, hence underscoring the important role for HBP1 in tumor suppression. The decreases in the HBP1 gene triggered an upregulation of TERT, of MYC and a downregulation of p16 INK4A , thus decreasing the need for exogenous TERT, MYC, and SV40 early region for in vitro transformation. Because HBP1 regulates Wnt signaling Kim et al., 2006) , the induction of MYC, a well-known Wnt target gene on HBP1 KD is plausible. Furthermore, our preliminary data and published data show that MYC and LEF/TCF sites (transcription factor recipients of Wnt signals) all contribute to TERT activation .
As shown in Figure 7 , the decrease in HBP1 led to an aggressive tumor in mice and thus orchestrated not only in vitro soft agar growth, but also full tumorigenesis. We have previously reported that decreased HBP1 and increased WIP1 (a p38 MAPK phosphatase expected to regulate p38MAPK activity in senescence) predict a poor prognosis in breast cancer . Indeed, decreases in HBP1 are associated with a poor prognosis in breast cancer (Paulson et al., 2007) . These later cancer-associated changes will be initiated by a loss of senescence that is triggered by the reduction in the HBP1 protein, of which the regulation of the p16 INK4A gene is a central factor. The data highlight a role for HBP1 in dictating tumor prognosis and the potentially deleterious consequences of reduced or mutant HBP1.
Together, the data in this article indicate that HBP1 has a central role in regulating p16
INK4A and other genes. These studies give important insights on how the reduction of a single factor can abrogate premature senescence to begin a cascade of events that leads to full tumorigenesis. The studies in this article are first steps toward understanding this circuitry, of which the HBP1-mediated regulation of the p16 INK4A gene has a central role. Together with our previously published work on a correlation of HBP1 decreases and mutations with an aggressive breast cancer, this study underscores the theses cancer-associated changes do have precise biologic consequence for transformation and tumorigenesis, perhaps with a poor prognosis. Our studies underscore the need to elevate HBP1 levels as part of therapeutic regiments to improve cancer prognosis.
Materials and methods

Cell proliferation
The cells were cultured in Dulbecco's modified Eagle's medium (Gibco) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA), 1 mM nonessential amino acids (Gibco, Grand Island, NY, USA), 10 mM sodium pyruvate (Cambrex, East Rutherford, NJ, USA), 20 mM glutamine (Gibco) and 1% penicillin G/streptomycin sulfate (Sigma, Santa Clara, CA, USA).
Retroviral gene expression pBabePuro-HBP1 and pBabePuro-delEx7 were constructed by cloning the respective human HBP1 fragment into pBabePuro (EcoRI). pBabePuro-pmHMG was generated by overlapping PCR based on pBabePuro-HBP1. Point mutations were introduced at the positions 434, 435 and 437 changing lysine-434 to glutamic acid (AAA to GAA), arginine 435 to glutamic acid (AGA to GAA) and methionine 437 to threonine (ATG to ACG). pBabeHygro-MKK6E was constructed by inserting the human MKK6(Glu) cDNA into pBabeHygro vector. GGAAA. Underlined sequences represent the hairpins. Retroviral gene transduction was carried out as previously described .
Knockdown plasmids
S-phase DNA synthesis
BrdU incorporation was carried out as the protocol of BrdU labeling and detection kit I (Roche, Basel, Switzerland, cat. no. 1296736). All coverslips were examined using fluorescence microscopy with the appropriate filters. At least 300 cells were counted in randomly chosen fields from each culture well.
Immunoblots and antibodies
Cells were lysed in RIPA buffer. Protein (20-50 mg) was separated on an SDS-10% polyacrylamide gel electrophoresis and transferred to Trans-Blot nitrocellulose membranes (Bio-Rad, Hercules, CA, USA). The primary antibodies used were for HBP1 (N-20X; Santa Cruz Biotechnology, Santa Cruz, CA, USA), p16 INK4A (C-20; Santa Cruz Biotechnology), p38 (A-12; Santa Cruz Biotechnology), phospho-p38 (no. 9211; Cell Signaling, Danvers, MA, USA) and HA.11 antibody (Covance, San Diego, CA, USA).
Senescence-associated-b-gal staining Cells were washed twice with phosphate-buffered saline, fixed for 3-5 min at room temperature in 3% formaldehyde and washed with phosphate-buffered saline again. Then, cells were incubated overnight at 37 1C with freshly prepared SA-b-gal stain solution (1mg/ml X-gal, 40 mM citric acid/sodium phosphate (pH 6.0), 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM NaCl, 2 mM MgCl 2 ). At least 300 cells were counted in randomly chosen fields (Shih et al., 2001) .
Electrophoretic mobility shift assay Nuclear extract (10 mg protein total) with 32 P-labeled DNA probe or cold competitor (if needed) was mixed in binding buffer (1 mg/ml poly-dIdC, 10 mM Tris-Cl (pH 8.0), 150 mM KCl, 0.5 mM EDTA, 0.1% Triton X-100, 12.5 % glycerol (v/v), 0.2 mM DTT). The reaction mixture was incubated for 30 min at room temperature. HA.11 antibody was included for supershift. Then the reaction mixture was incubated for additional 30 min at room temperature. Samples were run on acrylamide gel at 150 V for 2 h and the gel was transferred to Whatman paper. The top of gel was covered with Saran Wrap and dried in vacuum for 1-2 h and the gel was placed in cassette with reflection screen. Film was added and the gel was placed at À80 1C in a freezer.
Chromatin immunoprecipitation
The ChIP assay was performed as described . For the p16 INK4A promoter, the sequence to be amplified resides at positions À272 to À699. The PCR primer sequences were 5 0 -CCTTCCAATGACTCCCTC-3 0 and 5 0 -AACCTTCC TAACTGCCAAA-3 0 . The HBP1-binding site is located in the region from position À426 to À433.
RT-PCR
RNA was isolated using the Trizol reagent (Gibco BRL, Grand Island, NY, USA). RNA (1 mg) was analyzed by reverse transcription (RT)-PCR with an Access RT-PCR kit (Promega, San Luis Obispo, CA, USA). The DNA sequences of the human HBP1 primers were 5 0 -ATC ATCTCCTGTACACATCATAGC-3 0 and 5 0 -CATAGAAAG GGTGGTCCAGCTTAC-3 0 ; these primers resulted in an RT-PCR product of 523 bp. The DNA sequences of the human p16
INK4A primers were 5 0 -GCCGGCGGCGGGGAG CAGCATGG-3 0 and 5 0 -CAGCATTCGAGAGATCTGTAC GC-3 0 ; these primers resulted in an RT-PCR product of 379 bp. To normalize the RT-PCR results, we used GAPDH primers at a 1:10 ratio.
Soft agar assay
The growth of the transformation cells and control cells in soft agar was performed as described (Sokol et al., 2005) . In brief, cells (10 000 cells per plate) were grown in 0.3% agar on a cushion of 0.6% agar in 35 mm plates for 14 days, after which the colonies were observed under a light microscope.
Tumorigenicity assay
The NOD/SCID mice at age of 7 weeks were injected subcutaneously with 1 Â 10 6 cells in 100 ml of phosphatebuffered saline on the back. Five animals were used per cell line and were maintained on regular food and water.
